AMD

The Portal extension trial reveals that the Port Delivery System significantly improves vision in AMD patients, showcasing long-term efficacy and durability.

New treatments show promise in preventing fibrosis in neovascular AMD, addressing a critical need for improved visual outcomes in patients.

The company noted that this approval marks Celltrion's first Health Canada-approved biologic product in ophthalmology.

The investigators noted that this report is the first about subretinal drusenoid deposits in Black and Hispanic patients with age-related macular degeneration

Patient response focused on perceived vision-related quality of life outcomes, investigators said

The newly-approved technology delivers low-dose microcurrents through closed eyelids to stimulate retinal cells

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025

Presentation topics will include therapies for age-related macular degeneration, X-linked retinitis pigmentosa and other retinal pathologies

An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration

AMD treatment may become unrecognisable as gene therapies evolve

New financing will support the company's lead retinitis pigmentosa programme, among other projects

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

Long-term benefits and vision preservation using an extended macular vision IOL

Three dose level cohorts of the small interfering RNA therapeutic were evaluated in a double-blind study

Investigators sought to understand the diagnostic path, symptoms, quality of life impact and coping mechanisms of patients with GA in western Europe and the United States

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US